Analysts Set Atossa Genetics Inc. (NASDAQ:ATOS) PT at $20.33

Shares of Atossa Genetics Inc. (NASDAQ:ATOS) have received an average rating of “Hold” from the five analysts that are presently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation and three have given a buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $20.3333.

Several brokerages recently commented on ATOS. Weiss Ratings cut Atossa Genetics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 11th. Rodman & Renshaw assumed coverage on shares of Atossa Genetics in a report on Tuesday, July 7th. They set a “buy” rating and a $12.00 price target for the company. Finally, Wall Street Zen upgraded shares of Atossa Genetics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th.

Institutional Investors Weigh In On Atossa Genetics

Several large investors have recently modified their holdings of ATOS. XTX Topco Ltd lifted its holdings in Atossa Genetics by 581.2% in the fourth quarter. XTX Topco Ltd now owns 169,261 shares of the company’s stock valued at $100,000 after buying an additional 144,412 shares during the period. &PARTNERS bought a new stake in Atossa Genetics during the fourth quarter valued at $25,000. Graham Capital Management L.P. grew its holdings in Atossa Genetics by 27.8% during the 4th quarter. Graham Capital Management L.P. now owns 211,369 shares of the company’s stock worth $125,000 after acquiring an additional 45,923 shares during the period. State Street Corp grew its holdings in Atossa Genetics by 31.2% during the 4th quarter. State Street Corp now owns 596,485 shares of the company’s stock worth $352,000 after acquiring an additional 141,990 shares during the period. Finally, Renaissance Technologies LLC grew its holdings in Atossa Genetics by 33.2% during the 4th quarter. Renaissance Technologies LLC now owns 2,062,838 shares of the company’s stock worth $1,217,000 after acquiring an additional 514,175 shares during the period. 12.74% of the stock is currently owned by institutional investors and hedge funds.

Atossa Genetics Trading Down 2.3%

Shares of ATOS opened at $2.58 on Wednesday. The company has a market capitalization of $25.75 million, a PE ratio of -0.83 and a beta of 1.29. Atossa Genetics has a 12 month low of $1.70 and a 12 month high of $19.35. The stock’s 50-day moving average price is $2.34 and its two-hundred day moving average price is $3.93.

Atossa Genetics (NASDAQ:ATOS) last issued its quarterly earnings results on Friday, August 7th. The company reported ($0.95) earnings per share for the quarter, beating the consensus estimate of ($1.02) by $0.07. Equities research analysts predict that Atossa Genetics will post -3.95 EPS for the current fiscal year.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.